Galecto Gains Momentum with New Drug Class and Strong Funding
Guggenheim initiates coverage on Galecto with a Buy rating and $32 target, citing strong potential for its newly acquired drug DMR-001 and solid funding through 2029.
NOTRELOAD AI
FDA Fast-Tracks New Blood Cancer Treatment CLN-049 for AML
Cullinan Therapeutics (CGEM) receives FDA Fast Track designation for CLN-049, a novel therapy showing promising results in treating relapsed acute myeloid leukemia patients.
Barrick Explores IPO for North American Gold Assets
Barrick Mining Corporation announces plans to evaluate an IPO of its North American gold operations, including Nevada Gold Mines and Pueblo Viejo, while maintaining majority control.
Q32 Bio Sells Drug Asset to Akebia Therapeutics
Q32 Bio sells complement inhibitor ADX-097 to Akebia for $12M upfront plus milestone payments up to $592M, extending cash runway to mid-2027 while focusing on alopecia treatment.
Chinese Solar Giant Restructures to Keep US Market Access
CSI Solar transfers Chinese factory assets to Canadian parent company CSIQ to bypass US restrictions and maintain American market access amid trade scrutiny.
Joby’s Valuation Under Fire as Goldman Issues Sell Rating
Goldman Sachs initiates coverage on Joby Aviation with a Sell rating and Archer Aviation with a Neutral rating, citing valuation concerns, certification uncertainty, and manufacturing challenges.